Genetic deletion, pharmacological inhibition of the SHH-HSP90β axis, or delivery of miR-28-5p to macrophages in the male mice liver, impairs NASH symptomatic development. This evidence concerns the gene SHH and metabolic dysfunction-associated steatohepatitis.